LaminarPace is a novel ambient drying technology for biopharmaceuticals and vaccines that relies on mass transfer rather than heat transfer. By minimizing drying stress on active ingredients, LaminarPace enables the production of thermostable, particle-engineered dry powders that are easy to handle, transport, and suitable for alternative delivery routes. The platform has been successfully applied to mRNA, peptides, proteins, antibodies, lipids, enzymes, as well as excipients and adjuvants. 

Unlike traditional pharmaceutical drying systems that rely on heat transfer, LaminarPace utilizes mass transfer — a significantly more efficient drying method. Optimization tests show that after drying, less than 2% absolute humidity remains in the product. 

LaminarPace’s benefits extend well beyond the laboratory or use as a standalone formulation tool:

• It is an advanced, low-waste, high-yield drying system designed for industrial-scale pharmaceutical production.

• Ongoing development focuses on seamless industrial integration, leveraging mechanical engineering, 3D digital modeling, and cloud computing.

• LaminarPace is being engineered as a customizable, end-to-end solution—capable of integrating into existing manufacturing lines, from formulation and drying to fill-and-finish.

The portfolio includes patented and trademarked assets registered in the United States and European Union.

For licensing opportunities, please get in touch.